![if gte IE 9]> <![endif]>
Mozobil is approved by the FDA to be used in combination with another
agent granulocyte‑colony stimulating factor (G-CSF) to
mobilize hematopoietic stem cells to the peripheral blood for collection
and subsequent autologous transplantation in patients living with
non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM).
Our passion is to facilitate access and provide support to patients. Explore available resources, including the Sanofi Patient Connection Support Program.